Our Semaglutide represents the benchmark in high-purity metabolic research reagents, synthesized to mirror the precise mechanism of native glucagon-like peptide-1 (GLP-1) while featuring enhanced resistance to DPP-4 enzymatic degradation. This synthetic 31-amino-acid linear polypeptide sequence incorporates a specific fatty acid side chain modification that structurally extends its biological half-life and stability within experimental systems. By acting as a robust agonist at the GLP-1 receptor, this compound effectively regulates glucose-dependent insulin secretion, delays gastric emptying, suppresses appetite, and optimizes cellular metabolic pathways. It serves as a foundational tool in investigating treatment protocols for obesity, metabolic syndrome, and cardiovascular risk reduction.

To accommodate diverse laboratory and distribution frameworks, we offer this advanced peptide with fully customizable packaging layouts and box designs. Rather than limiting your supply to a single format, you can select from an array of specifications tailored directly to your brand or research requirements. Our available stock includes classic lyophilized powder configurations (spanning standard weight increments from 2mg up to 50mg packaged securely at 10 vials per box), ready-to-ship card tubes without pens for rapid integration, oral tablets for alternative ingestion models (3mg, 7mg, and 14mg), and raw bulk powder volumes for large-scale compounding.

Packaging Varieties:

• Lyophilized Powder Vials: 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, and 50mg specifications (10 vials per box).

• Cartridge Formats: Ready-to-ship card tubes without pens (available in 2mg and 5mg specifications; 10 vials per box).

• Alternative Forms: Pre-formulated liquid injectables, custom oral tablets (3mg, 7mg, and 14mg), or raw loose bulk powder material (available in 1g, 2g, and higher wholesale weights)